Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases
- 8 February 2020
- journal article
- review article
- Published by Informa UK Limited in Expert Review of Clinical Immunology
- Vol. 16 (3), 311-319
- https://doi.org/10.1080/1744666x.2020.1724089
Abstract
Introduction: The development of new biologic agents has provided definite therapeutic advances but, like with any new medications, safety remains a concern. Areas covered: Using PubMed, we reviewed the literature on the adverse effects (AE) to five biologics approved for asthma and/or allergic diseases: one anti-IgE (omalizumab), three anti-IL5 (mepolizumab, reslizumab, benralizumab), and one anti-IL4 (dupilumab). Expert opinion: Biologic agents approved for asthma and allergic diseases are generally safe. Most common AE are benign and tolerated, though long-term safety is lacking for most of them. A slightly increased risk of anaphylaxis to omalizumab and reslizumab required the inclusion of a black box warning, informing the patient, the need for post-injection observation period, and the provision of epinephrine autoinjectors for self-administration when needed. Hypersensitivity reactions, mainly urticaria and very rarely serum sickness have occurred.Keywords
This publication has 65 references indexed in Scilit:
- Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trialJournal of Allergy and Clinical Immunology, 2011
- An Antibody Against IL-5 Reduces Numbers of Esophageal Intraepithelial Eosinophils in Children With Eosinophilic EsophagitisGastroenterology, 2011
- Omalizumab in the treatment of eosinophilic esophagitis and food allergyEuropean Journal of Pediatrics, 2011
- The Safety and Interpretability of Skin Tests with OmalizumabAnnals of Allergy, Asthma & Immunology, 2010
- Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trialGut, 2009
- Safety and tolerability of omalizumabClinical and Experimental Allergy, 2009
- Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapyJournal of Allergy and Clinical Immunology, 2008
- American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxisJournal of Allergy and Clinical Immunology, 2007
- Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin (Case Report)Nephrology, 2005
- Allergic asthma and an anti-CD23 mAb (IDEC-152) Results of a phase I, single-dose, dose-escalating clinical trialJournal of Allergy and Clinical Immunology, 2003